# SOBR Safe, Inc.: financial statements, quarterly

SOBR · OTC · CIK 1425627 · [Communication](/sectors/communication.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sobr.md) · [Financials](/companies/sobr/financials.md) · [Filings](/companies/sobr/filings.md) · [Insiders](/companies/sobr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sobr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [36.3](/filings/0001477932-24-007122.md) | [35.5 d](/filings/0001477932-25-002746.md) | [48.0](/filings/0001477932-25-003898.md) | [54.2](/filings/0001477932-25-005544.md) | [46.1](/filings/0001477932-25-008092.md) | [64.4 d](/filings/0001477932-26-002117.md) | [86.6](/filings/0001477932-26-002680.md) | [104](/filings/0001477932-26-005085.md) | [109](/filings/0001477932-25-008092.md) | [138 d](/filings/0001477932-26-002117.md) | [79.0](/filings/0001477932-26-002680.md) | [29.1](/filings/0001477932-26-005085.md) |
| Cost of revenue | $k | [20.2](/filings/0001477932-24-007122.md) | [28.1 d](/filings/0001477932-25-002746.md) | [24.8](/filings/0001477932-25-003898.md) | [41.2](/filings/0001477932-25-005544.md) | [16.0](/filings/0001477932-25-008092.md) | [112 d](/filings/0001477932-26-002117.md) | [35.7](/filings/0001477932-26-002680.md) | [44.3](/filings/0001477932-26-005085.md) | [71.0](/filings/0001477932-25-008092.md) | [50.9 d](/filings/0001477932-26-002117.md) | [34.1](/filings/0001477932-26-002680.md) | [146](/filings/0001477932-26-005085.md) |
| Gross profit | $k | [16.1](/filings/0001477932-24-007122.md) | [7.4 d](/filings/0001477932-25-002746.md) | [23.2](/filings/0001477932-25-003898.md) | [13.0](/filings/0001477932-25-005544.md) | [30.1](/filings/0001477932-25-008092.md) | [(47.2) d](/filings/0001477932-26-002117.md) | [51.0](/filings/0001477932-26-002680.md) | [59.9](/filings/0001477932-26-005085.md) | [37.9](/filings/0001477932-25-008092.md) | [86.8 d](/filings/0001477932-26-002117.md) | [44.9](/filings/0001477932-26-002680.md) | [(117)](/filings/0001477932-26-005085.md) |
| Research and development | $k | [214](/filings/0001477932-24-007122.md) | [428 d](/filings/0001477932-25-002746.md) | [102](/filings/0001477932-25-003898.md) | [308](/filings/0001477932-25-005544.md) | [194](/filings/0001477932-25-008092.md) | [143 d](/filings/0001477932-26-002117.md) | [40.9](/filings/0001477932-26-002680.md) | [199](/filings/0001477932-26-005085.md) | [30.1](/filings/0001477932-25-008092.md) | [60.0 d](/filings/0001477932-26-002117.md) | [23.7](/filings/0001477932-26-002680.md) | [7.0](/filings/0001477932-26-005085.md) |
| Operating income | $k | [(2,067)](/filings/0001477932-24-007122.md) | [(2,387) d](/filings/0001477932-25-002746.md) | [(1,709)](/filings/0001477932-25-003898.md) | [(1,877)](/filings/0001477932-25-005544.md) | [(1,848)](/filings/0001477932-25-008092.md) | [(2,242) d](/filings/0001477932-26-002117.md) | [(1,953)](/filings/0001477932-26-002680.md) | [(2,069)](/filings/0001477932-26-005085.md) | [(2,225)](/filings/0001477932-25-008092.md) | [(2,911) d](/filings/0001477932-26-002117.md) | [(2,310)](/filings/0001477932-26-002680.md) | [(3,067)](/filings/0001477932-26-005085.md) |
| Interest expense | $k | [179](/filings/0001477932-24-007122.md) | [191 d](/filings/0001477932-25-002746.md) | [233](/filings/0001477932-25-003898.md) | [213](/filings/0001477932-25-005544.md) | [5.9](/filings/0001477932-25-008092.md) | [5.9 d](/filings/0001477932-26-002117.md) | [3.7](/filings/0001477932-26-002680.md) | [2.1](/filings/0001477932-26-005085.md) | [9.0](/filings/0001477932-25-008092.md) | [7.0 d](/filings/0001477932-26-002117.md) | [3.5](/filings/0001477932-26-002680.md) | [1.8](/filings/0001477932-26-005085.md) |
| Income tax | $k | [0.0](/filings/0001477932-24-007122.md) | [0.0 d](/filings/0001477932-25-002746.md) | [0.0](/filings/0001477932-25-003898.md) | [0.0](/filings/0001477932-25-005544.md) | [0.0](/filings/0001477932-25-008092.md) | [0.0 d](/filings/0001477932-26-002117.md) | [0.0](/filings/0001477932-26-002680.md) | [0.0](/filings/0001477932-26-005085.md) | [0.0](/filings/0001477932-25-008092.md) | [0.0 d](/filings/0001477932-26-002117.md) | [0.0](/filings/0001477932-26-002680.md) | [0.0](/filings/0001477932-26-005085.md) |
| Net income | $k | [(2,197)](/filings/0001477932-24-007122.md) | [(2,542) d](/filings/0001477932-25-002746.md) | [2,506](/filings/0001477932-25-003898.md) | [(2,077)](/filings/0001477932-25-005544.md) | [(1,841)](/filings/0001477932-25-008092.md) | [(2,185) d](/filings/0001477932-26-002117.md) | [(1,879)](/filings/0001477932-26-002680.md) | [(1,995)](/filings/0001477932-26-005085.md) | [(2,187)](/filings/0001477932-25-008092.md) | [(2,890) d](/filings/0001477932-26-002117.md) | [(2,293)](/filings/0001477932-26-002680.md) | [(3,062)](/filings/0001477932-26-005085.md) |
| Diluted EPS | $ per share | [(13.42)](/filings/0001477932-24-007122.md) | not reported | [(232.21)](/filings/0001477932-25-003898.md) | [(113.76)](/filings/0001477932-25-005544.md) | [(58.26)](/filings/0001477932-25-008092.md) | not reported | [(1.46)](/filings/0001477932-26-002680.md) | [(1.32)](/filings/0001477932-26-005085.md) | [(1.44)](/filings/0001477932-25-008092.md) | not reported | [(0.92)](/filings/0001477932-26-002680.md) | [(1.08)](/filings/0001477932-26-005085.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.1](/filings/0001477932-23-008193.md) | [2.8](/filings/0001477932-24-001629.md) | [1.3](/filings/0001477932-24-002962.md) | [2.2](/filings/0001477932-24-004685.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.4](/filings/0001477932-26-005085.md) |
| Current assets | $m | [4.7](/filings/0001477932-23-008193.md) | [3.4](/filings/0001477932-25-002746.md) | [1.9](/filings/0001477932-24-002962.md) | [2.6](/filings/0001477932-24-004685.md) | [0.9](/filings/0001477932-24-007122.md) | [8.9](/filings/0001477932-26-002117.md) | [10.5](/filings/0001477932-25-003898.md) | [8.8](/filings/0001477932-25-005544.md) | [5.2](/filings/0001477932-25-008092.md) | [5.2](/filings/0001477932-26-005085.md) | [2.5](/filings/0001477932-26-002680.md) | [0.5](/filings/0001477932-26-005085.md) |
| Total assets | $m | [7.6](/filings/0001477932-23-008193.md) | [6.1](/filings/0001477932-25-002746.md) | [4.5](/filings/0001477932-24-002962.md) | [5.1](/filings/0001477932-24-004685.md) | [3.3](/filings/0001477932-24-007122.md) | [11.2](/filings/0001477932-26-002117.md) | [12.7](/filings/0001477932-25-003898.md) | [10.9](/filings/0001477932-25-005544.md) | [7.2](/filings/0001477932-25-008092.md) | [6.6](/filings/0001477932-26-005085.md) | [3.8](/filings/0001477932-26-002680.md) | [0.6](/filings/0001477932-26-005085.md) |
| Current liabilities | $m | [1.0](/filings/0001477932-23-008193.md) | [1.5](/filings/0001477932-25-002746.md) | [3.4](/filings/0001477932-24-002962.md) | [1.3](/filings/0001477932-24-004685.md) | [1.2](/filings/0001477932-24-007122.md) | [1.3](/filings/0001477932-26-002117.md) | [1.1](/filings/0001477932-25-003898.md) | [2.8](/filings/0001477932-25-005544.md) | [1.2](/filings/0001477932-25-008092.md) | [1.7](/filings/0001477932-26-005085.md) | [1.1](/filings/0001477932-26-002680.md) | [0.9](/filings/0001477932-26-005085.md) |
| Total liabilities | $m | [3.5](/filings/0001477932-23-008193.md) | [4.2](/filings/0001477932-25-002746.md) | [3.6](/filings/0001477932-24-002962.md) | [1.4](/filings/0001477932-24-004685.md) | [1.3](/filings/0001477932-24-007122.md) | [1.4](/filings/0001477932-26-002117.md) | [1.1](/filings/0001477932-25-003898.md) | [2.8](/filings/0001477932-25-005544.md) | [1.2](/filings/0001477932-25-008092.md) | [1.7](/filings/0001477932-26-005085.md) | [1.1](/filings/0001477932-26-002680.md) | [0.9](/filings/0001477932-26-005085.md) |
| Long-term debt | $m | not reported | [2.3](/filings/0001477932-24-007122.md) | [0.0](/filings/0001477932-24-002962.md) | [0.0](/filings/0001477932-24-004685.md) | [0.0](/filings/0001477932-24-007122.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [0.1](/filings/0001477932-25-002746.md) | not reported | [0.0](/filings/0001477932-24-004685.md) | [0.2](/filings/0001477932-24-007122.md) | [0.1](/filings/0001477932-25-003898.md) | [0.0](/filings/0001477932-25-003898.md) | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [4.2](/filings/0001477932-23-008193.md) | [2.0](/filings/0001477932-25-005544.md) | [0.9](/filings/0001477932-25-005544.md) | [3.7](/filings/0001477932-25-005544.md) | [2.1](/filings/0001477932-24-007122.md) | [9.9](/filings/0001477932-26-002117.md) | [11.6](/filings/0001477932-25-005544.md) | [8.0](/filings/0001477932-25-005544.md) | [6.0](/filings/0001477932-25-008092.md) | [5.0](/filings/0001477932-26-005085.md) | [2.7](/filings/0001477932-26-002680.md) | [(0.3)](/filings/0001477932-26-005085.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,442) d](/filings/0001477932-24-007122.md) | [(1,223) d](/filings/0001477932-25-002746.md) | [(1,454)](/filings/0001477932-25-003898.md) | [(1,595) d](/filings/0001477932-25-005544.md) | [(1,862) d](/filings/0001477932-25-008092.md) | [(1,611) d](/filings/0001477932-26-002117.md) | [(1,705)](/filings/0001477932-26-002680.md) | [(1,608) d](/filings/0001477932-26-005085.md) | [(2,017) d](/filings/0001477932-25-008092.md) | [(1,627) d](/filings/0001477932-26-002117.md) | [(2,591)](/filings/0001477932-26-002680.md) | [(1,768) d](/filings/0001477932-26-005085.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001477932-26-002117.md) | not reported | not reported | not reported | [0.0 d](/filings/0001477932-26-002117.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [164](/filings/0001477932-24-007122.md) | [17.3](/filings/0001477932-25-003898.md) | [21.3](/filings/0001477932-25-005544.md) | [31.6](/filings/0001477932-25-008092.md) | [1,321](/filings/0001477932-26-002680.md) | [1,516](/filings/0001477932-26-005085.md) | [1,516](/filings/0001477932-25-008092.md) | [2,496](/filings/0001477932-26-002680.md) | [2,843](/filings/0001477932-26-005085.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,387,210 at 2026-08-13, from the cover of the [10-Q filed 2026-08-14](/filings/0001477932-26-005085.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.